Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026

Core Insights - Kyverna Therapeutics is set to present key findings from its KYSA-8 trial for Stiff Person Syndrome (SPS) and updated data from the KYSA-6 trial for generalized myasthenia gravis (gMG) at the American Academy of Neurology Annual Meeting in April 2026 [1][2] Company Overview - Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, with its lead product being miv-cel (KYV-101), a CD19-targeting CAR T-cell therapy [9] - The company aims to redefine treatment paradigms for SPS and myasthenia gravis through innovative therapies [2][9] Clinical Trials and Presentations - The oral presentation for the KYSA-8 trial will showcase the efficacy and safety of miv-cel in treating SPS, with a focus on reversing progressive disability [3][4] - Updated Phase 2 results for the KYSA-6 trial will be presented, which investigates miv-cel's potential to achieve durable, drug-free, disease-free remission with a single dose in gMG patients [2][3] Disease Context - Stiff Person Syndrome (SPS) is a rare autoimmune disease characterized by muscle stiffness and spasms, leading to significant mobility issues, with no FDA-approved treatments currently available [5] - Generalized myasthenia gravis (gMG) is an autoimmune neuromuscular disease that causes muscle weakness and fatigue, affecting approximately 80,000 patients in the U.S. [6][7] Product Information - Miv-cel is designed for potency and tolerability, aiming for deep B-cell depletion and immune system reset, which could lead to long-lasting remission in autoimmune diseases [8]